- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04:22 | Celltrion Launches Stelkima and Omliklo in Australia, Accelerating Market Share Expansion | 1 | BusinessKorea | ||
| 03:38 | Celltrion to strengthen biosimilar lineup in Australia | 2 | Yonhap News | ||
| Mo | Celltrion Enters Phase 3 European Trial for Darzalex Biosimilar | 1 | BusinessKorea | ||
| 28.08. | Celltrion aims to strengthen biosimilar lineup in Vietnam | 1 | Yonhap News | ||
| 28.08. | Celltrion Launches Remsima and Herzuma in Vietnam | 1 | BusinessKorea | ||
| CELLTRION Aktie jetzt für 0€ handeln | |||||
| 27.08. | Prometheus Laboratories Announces Collaboration with Celltrion for Anser Testing | 192 | ACCESS Newswire | Therapeutic Drug Monitoring Test Validated for Subcutaneous Infliximab SAN DIEGO, CA / ACCESS Newswire / August 27, 2025 / Prometheus Laboratories Inc. ("Prometheus"), a leader in precision healthcare... ► Artikel lesen | |
| 22.08. | FDA approves Celltrion's Actemra biosimilar Avtozma for cytokine release syndrome | 1 | PMLiVE | ||
| 14.08. | Celltrion Short Selling Triples Overnight | 1 | BusinessKorea | ||
| 12.08. | Celltrion gains ground as one of most-prescribed drug suppliers in Italy | - | Korea Economic Daily | ||
| 12.08. | Celltrion expands presence in Italy with autoimmune, anticancer drugs | 1 | Korea Herald | ||
| 12.08. | Celltrion Expands Autoimmune and Cancer Drug Orders in Italy | 1 | BusinessKorea | ||
| 11.08. | FDA Approves Expanded Indication for Celltrion's AVTOZMA | 1 | Contract Pharma | ||
| 08.08. | Celltrion in talks to buy Eli Lilly plant in US for $504 million | 22 | Korea Economic Daily | ||
| 06.08. | Celltrion: FDA approves expanded indication for AVTOZMA (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS) | 83 | PR Newswire | Approval of AVTOZMA® (tocilizumab-anoh) intravenous infusion expands label to include treatment of adults and pediatric patients aged 2 years and older with cytokine... ► Artikel lesen | |
| 06.08. | Celltrion's Q2 net falls 19.3% on provisions | 2 | Korea Herald | ||
| 30.07. | Celltrion closes in on US plant purchase, dubbing drug substance facility 'fundamental' to tariff mitigation | 2 | FiercePharma | ||
| 29.07. | Celltrion nears deal for first US biologic manufacturing plant | - | Korea Economic Daily | ||
| 29.07. | Celltrion seeks to acquire major biopharmaceutical plant in U.S. by October as Trump tariff hedge | 2 | Korea Joongang Daily | ||
| 29.07. | Korea's Celltrion says tapped to buy U.S. pharma factory to offset tariff risk | 1 | Korea Joongang Daily | ||
| 29.07. | Celltrion to acquire US plant for $500 mil. to mitigate tariff risks | 2 | Korea Times |
1 2 3 4 5 Weiter >>
116 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,215 | +0,11 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
| EVOTEC | 5,702 | -2,70 % | Deutsche Bank Aktie: Viel zu teuer? - Evotec, Hensoldt, Nel ASA, Nvidia und Vossloh im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| BIONTECH | 89,10 | +3,42 % | BioNtech Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| MINERALYS THERAPEUTICS | 31,520 | +7,76 % | Jefferies raises Mineralys Therapeutics stock price target to $26 from $15 | ||
| RECURSION PHARMACEUTICALS | 4,530 | -2,16 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
| SUMMIT THERAPEUTICS | 23,730 | +0,89 % | Summit Therapeutics stock maintains Buy rating at H.C. Wainwright on ivonescimab progress | ||
| BOLT PROJECTS | 4,070 | +40,83 % | Bolt Projects Holdings, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 16,640 | -1,54 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 10,415 | -4,27 % | Roth/MKM initiates ARS Pharmaceuticals stock with Buy rating on neffy potential | ||
| VALNEVA | 3,768 | -1,26 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH
29.08.2025 / 16:48 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 19,410 | -1,82 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 11,600 | -2,52 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 3,235 | +11,55 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from... ► Artikel lesen | |
| NOVAVAX | 6,656 | +4,92 % | Novavax gets Japan nod for its COVID-19 vaccine, triggers Takeda payment | ||
| BEAM THERAPEUTICS | 18,360 | -2,13 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen |
CELLTRION INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CELLTRION INC finden Sie auf Wallstreet Online.